Hammered hard by a surprising FDA rejection, Ionis spinout Akcea offers an explanation and then chops 1-in-10 staffers
Akcea reported in an SEC filing Thursday afternoon that it is chopping 10% of its workforce as a result of the FDA’s surprise rejection …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
